Home » Stocks » TGTX

TG Therapeutics, Inc. (TGTX)

Stock Price: $43.77 USD 0.27 (0.62%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $44.98 +1.21 (2.76%) Feb 26, 5:14 PM
Market Cap 6.03B
Revenue (ttm) 152,000
Net Income (ttm) -230.74M
Shares Out 119.18M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $43.77
Previous Close $43.50
Change ($) 0.27
Change (%) 0.62%
Day's Open 44.23
Day's Range 42.42 - 44.82
Day's Volume 1,201,572
52-Week Range 6.34 - 56.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

Large biotechs are taking over small-cap companies (and their cancer treatments) left and right. Could this business be the next target?

Other stocks mentioned: IBB
GlobeNewsWire - 3 weeks ago

UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

GlobeNewsWire - 1 month ago

Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET

CNBC Television - 1 month ago

TG Therapeutics CEO on developing treatments for patients with multiple sclerosis

TG Therapeutics CEO Mike Weiss explained the biopharmaceutical company's plans to address the multiple sclerosis drug market and carve a lane away from competitors in the space.

GlobeNewsWire - 1 month ago

Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET

GuruFocus - 1 month ago

After a protracted wait, TG Therapeutics Inc. (NASDAQ:TGTX) shareholders finally got rewarded for their patience last month when the stock began a rapid climb to its current price of $52. That...

Zacks Investment Research - 1 month ago

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Other stocks mentioned: BLFS, STAA
Zacks Investment Research - 2 months ago

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

The Motley Fool - 2 months ago

These biotech stocks could sink or soar following some important approval decisions slated for the new year.

Other stocks mentioned: BIIB, BLUE
Seeking Alpha - 2 months ago

Umbralisib and ublituximab have excellent chances of gaining FDA approval for various blood cancers next year. TGTX also recently reported robust data for ublituximab as a treatment for relaps...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), t...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG ...

Investors Business Daily - 2 months ago

TG Therapeutics stock jumped after the biotech firm announced positive top-line results from two phase 3 studies for its Ublituximab treatment of multiple sclerosis patients. The post TG Thera...

GlobeNewsWire - 2 months ago

Both studies met their primary endpoint of significantly reducing annualized relapse rate ( ARR ) (p

GuruFocus - 2 months ago

Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the third quarter of 2020, which ended on Sept. 30.

Other stocks mentioned: GLW, LOGI, LRCX
GlobeNewsWire - 2 months ago

UNITY-CLL: U2 significantly improved progression-free survival over obin utuz u mab plus chlorambucil (HR= 0 .54, p

GlobeNewsWire - 2 months ago

U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow

Seeking Alpha - 2 months ago

Since last year, TGTX has executed its programs brilliantly. Cash position also is decent, although I expect some justified dilution before revenue generation.

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigation...

GlobeNewsWire - 2 months ago

Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET

GlobeNewsWire - 3 months ago

Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT

Insider Monkey - 3 months ago

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and anal...

Zacks Investment Research - 3 months ago

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company develop...

GlobeNewsWire - 3 months ago

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR= 0 .54, p

Zacks Investment Research - 3 months ago

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the com...

GlobeNewsWire - 5 months ago

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Compan...

Benzinga - 6 months ago

TG Therapeutics (NASDAQ: TGTX) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients w...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Applica...

Seeking Alpha - 6 months ago

TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developme...

Zacks Investment Research - 7 months ago

Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 7 months ago

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 7 months ago

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbrali...

GlobeNewsWire - 8 months ago

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced...

GlobeNewsWire - 8 months ago

Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET

GlobeNewsWire - 8 months ago

NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25th European Hematology Association (EHA) annual congress includi...

The Motley Fool - 8 months ago

The development-stage company appears to be on the path to commercial operations.

GlobeNewsWire - 8 months ago

Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET

GlobeNewsWire - 8 months ago

The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy

InvestorPlace - 8 months ago

With the worst of the coronavirus priced into markets, the U.S. economy is slowly reopening, serving as another boon for small-cap stocks.

Other stocks mentioned: GLUU, INSG
GlobeNewsWire - 9 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), ...

GlobeNewsWire - 9 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG...

InvestorPlace - 9 months ago

By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.

Other stocks mentioned: CRSP, MRNA
GlobeNewsWire - 9 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology...

GlobeNewsWire - 9 months ago

NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Con...

GlobeNewsWire - 9 months ago

$40 million of which came from longtime shareholder, RA Capital Management $40 million of which came from longtime shareholder, RA Capital Management

Zacks Investment Research - 9 months ago

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About TGTX

TG Therapeutics, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic... [Read more...]

Industry
Biotechnology
IPO Date
Dec 14, 1995
CEO
Michael Weiss
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
TGTX
Full Company Profile

Financial Performance

In 2019, TGTX's revenue was $152,000, a change of 0.00% compared to the previous year's $152,000. Losses were -$172.87 million, -0.35% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is 76.00, which is an increase of 73.63% from the latest price.

Price Target
$76.00
(73.63% upside)
Analyst Consensus: Strong Buy